TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15245622

Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment (ACT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Brokered Case Management (BCM)
Number of subjects: 0
Study: 11359482

Group type: EXPERIMENTAL
Intervention: Tooth-implant connected prostheses
Number of subjects: 123

Group type: COMPARATOR
Intervention: Freestanding implant-supported prostheses
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Rigid tooth-implant connected prostheses
Number of subjects: 123
Study: 9413883

Group type: EXPERIMENTAL
Intervention: Short allele of the serotonin transporter gene
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (150 individuals)
Number of subjects: 66
Study: 8481748

Group type: EXPERIMENTAL
Intervention: Caffeinated products
Number of subjects: 26

Group type: COMPARATOR
Intervention: Decaffeinated products
Number of subjects: 26
Study: 3436154

Group type: EXPERIMENTAL
Intervention: Isoxicam (400 mg single dose)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Isoxicam (repeated dosing)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Isoxicam (compared to younger healthy population)
Number of subjects: 19
Study: 31065236

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Upper- and lower-cycle (ULC)
Number of subjects: 60
Study: 29029101

Group type: EXPERIMENTAL
Intervention: GH therapy (0.056 mg/kg/d for a median duration of 6.5 years)
Number of subjects: 58
Study: 25234274

Group type: EXPERIMENTAL
Intervention: Peer assessment (PA)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Usual case discussion (CD)
Number of subjects: 149
Study: 22554679

Group type: EXPERIMENTAL
Intervention: Domperidone 10 mg 3 times daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Domperidone 20 mg 3 times daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 21733727

Group type: EXPERIMENTAL
Intervention: Amikacin 7.5 mg/kg every 8 h (MDD)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Amikacin 22.5 mg/kg as a single dose (ODD)
Number of subjects: 100
Study: 19808139

Group type: EXPERIMENTAL
Intervention: Biogeneric abciximab
Number of subjects: 37

Group type: COMPARATOR
Intervention: Branded abciximab
Number of subjects: 37
Study: 16786822

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) for anxiety
Number of subjects: 36

Group type: COMPARATOR
Intervention: Children with comorbid anxiety and asthma
Number of subjects: 36
Study: 15297066

Group type: EXPERIMENTAL
Intervention: Fluarix plus 1mg CPG 7909
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fluarix plus saline control
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluarix (1/10th dose)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluarix (full dose)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fluarix plus 1mg CPG 7909 (in individuals with pre-existing immunity)
Number of subjects: 60
Study: 12126992

Group type: EXPERIMENTAL
Intervention: High arousal condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate arousal condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low arousal condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderately novel foods
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extremely novel foods
Number of subjects: 0
Study: 9579717

Group type: EXPERIMENTAL
Intervention: Roxithromycin 300 mg once daily for 8-10 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cefixime 400 mg once daily for 8-10 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Roxithromycin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cefixime
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study: 7900711

Group type: EXPERIMENTAL
Intervention: Lorazepam (as an adjunct to metoclopramide, dexamethasone, and clemastine)
Number of subjects: 180
Study: 2767201

Group type: EXPERIMENTAL
Intervention: Convergence eye movements with a 20 ms vertical displacement pulse (up to 0.5 degrees)
Number of subjects: 3
Study: 264440

Group type: EXPERIMENTAL
Intervention: Epithelium-containing graft from the hard palate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epithelium-free graft from the hard palate
Number of subjects: 0
Study: 31590069

Group type: EXPERIMENTAL
Intervention: Short-foot exercise (3 times per week for 8 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study: 30020450

Group type: EXPERIMENTAL
Intervention: 3D printed models for training in flexible bronchoscopy (Model 2)
Number of subjects: 10
Study: 27500949

Group type: EXPERIMENTAL
Intervention: Prefilled syringe (PFS)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Autoinjector
Number of subjects: 204

Group type: COMPARATOR
Intervention: Comparison of autoinjector to PFS
Number of subjects: 204
Study: 26299217

Group type: EXPERIMENTAL
Intervention: Community-based lifestyle program for smoking cessation (Luchtsignaal(®))
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Community-based lifestyle program for weight loss (Weight Watchers(®))
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Community-based lifestyle program for improving physical activity (Philips DirectLife(®))
Number of subjects: 800

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 800
Study: 24793528

Group type: EXPERIMENTAL
Intervention: 0.5 mg conbercept (PRN)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 0.5 mg conbercept (Q1M)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 2.0 mg conbercept (PRN)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: 2.0 mg conbercept (Q1M)
Number of subjects: 122

Group type: COMPARATOR
Intervention: 0.5 mg conbercept
Number of subjects: 122

Group type: COMPARATOR
Intervention: 2.0 mg conbercept
Number of subjects: 122
Study: 22573504

Group type: EXPERIMENTAL
Intervention: REHACOP
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (occupational therapy)
Number of subjects: 76
Study: 19304712

Group type: EXPERIMENTAL
Intervention: 100 kV and 330 mAs
Number of subjects: 100

Group type: COMPARATOR
Intervention: 120 kV and 330 mAs
Number of subjects: 100
Study: 17332788

Group type: COMPARATOR
Intervention: Insulin stimulation alone
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Insulin stimulation with superimposed exercise
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Exercise-induced glucose uptake
Number of subjects: 4
Study: 15447902

Group type: EXPERIMENTAL
Intervention: Low-phosphate iron mineral ferritin
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High-phosphate iron mineral ferritin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ferrous sulfate
Number of subjects: 30
Study: 11251695

Group type: EXPERIMENTAL
Intervention: Gabapentin (2400 mg/day)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study: 9672272

Group type: COMPARATOR
Intervention: Stenting plus placebo
Number of subjects: 2399

Group type: EXPERIMENTAL
Intervention: Stenting plus abciximab
Number of subjects: 2399

Group type: EXPERIMENTAL
Intervention: Balloon angioplasty plus abciximab
Number of subjects: 2399

Group type: EXPERIMENTAL
Intervention: Major bleeding complications
Number of subjects: 2399
Study: 8021054

Group type: EXPERIMENTAL
Intervention: Prazosin 1 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31216584

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 29778481

Group type: EXPERIMENTAL
Intervention: Anti-IL-10 egg yolk antibodies (MAB, n = 71)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group without anti-IL-10 antibodies (MEP, n = 62)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Anti-IL-10 egg yolk antibodies (MAB)
Number of subjects: 133
Study: 27448478

Group type: EXPERIMENTAL
Intervention: Sleep for Success program (SFS)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 71
Study: 24532651

Group type: EXPERIMENTAL
Intervention: Community-based management of under-5 fever
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Younger age groups (15-25 years)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Age group 26-45 years
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Age group ≥46 years
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Community approval of CHWs
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Approval by CHW's immediate family
Number of subjects: 520
Study: 21983163

Group type: EXPERIMENTAL
Intervention: Once-daily dosing of 10mg rosuvastatin
Number of subjects: 37

Group type: COMPARATOR
Intervention: Alternate-day dosing of 10mg rosuvastatin
Number of subjects: 37
Study: 21250575

Group type: EXPERIMENTAL
Intervention: Quartz fiber posts (Endo Light post) cemented using dual cured resin cement (Prime & Bond NT + Fluorocore 2) with post space depth of 5 mm
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Quartz fiber posts (Endo Light post) cemented using dual cured resin cement (Prime & Bond NT + Fluorocore 2) with post space depth of 7 mm
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Quartz fiber posts (Endo Light post) cemented using dual cured resin cement (Prime & Bond NT + Fluorocore 2) with post space depth of 9 mm
Number of subjects: 30
Study: 18445991

Group type: EXPERIMENTAL
Intervention: LOS group (losartan 25 mg alone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LOS+BUC group (losartan 25 mg after bucolome 300 mg for 7 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group A (losartan 10 mg/kg for 14 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group B (losartan 10 mg/kg and bucolome 50 mg/kg for 14 days)
Number of subjects: 0
Study: 16330675

Group type: EXPERIMENTAL
Intervention: Doxorubicin-cisplatin (AP) chemotherapy (60 mg/m2 doxorubicin and 50 mg/m2 cisplatin every 3 weeks for seven cycles, followed by one cycle of cisplatin)
Number of subjects: 422

Group type: COMPARATOR
Intervention: Whole-abdominal irradiation (WAI) (30 Gy in 20 fractions, with a 15-Gy boost)
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Doxorubicin-cisplatin (AP) chemotherapy
Number of subjects: 422

Group type: COMPARATOR
Intervention: Whole-abdominal irradiation (WAI)
Number of subjects: 422
Study: 14616410

Group type: EXPERIMENTAL
Intervention: Voriconazole + Warfarin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo + Warfarin
Number of subjects: 0
Study: 11015972

Group type: EXPERIMENTAL
Intervention: Immediate referral for colposcopy at enrollment
Number of subjects: 5020

Group type: EXPERIMENTAL
Intervention: Follow-up with cytology only
Number of subjects: 5020

Group type: EXPERIMENTAL
Intervention: Use of HPV DNA testing to triage to colposcopy
Number of subjects: 5020
Study: 8928327

Group type: EXPERIMENTAL
Intervention: Classic approach F.A. Gotch
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Estimation according to E.G. Lowrei
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Estimation according to R.M. Hakim
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Estimation according to K.K. Jindal
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Estimation according to P. Calzavara
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Estimation according to J.T. Daugirdas
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Estimation according to C. Basile
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Estimation according to P. Malchesky
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Estimation according to L. Garred et. al.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Estimation according to approaches 2, 8 and 9
Number of subjects: 120
Study: 1623493

Group type: EXPERIMENTAL
Intervention: NGLDM method
Number of subjects: 1290

Group type: EXPERIMENTAL
Intervention: Circular symmetric autoregressive random field model
Number of subjects: 1290

Group type: EXPERIMENTAL
Intervention: Peak-variance method
Number of subjects: 1290
Study: 6144829

Group type: EXPERIMENTAL
Intervention: Intradermal HDCV (0.1 ml doses)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Intramuscular HDCV (1.0 ml doses)
Number of subjects: 94
Study: 30086057

Group type: EXPERIMENTAL
Intervention: Posterior tibial nerve stimulation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 27216112

Group type: EXPERIMENTAL
Intervention: Digital Cognitive Behavioural Therapy (dCBT) delivered via web and/or mobile channels
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Sleep hygiene education (SHE) comprising a website plus a downloadable booklet
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Digital Cognitive Behavioural Therapy (dCBT)
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Sleep hygiene education (SHE)
Number of subjects: 1000
Study: 25244260

Group type: EXPERIMENTAL
Intervention: Moderate intensity continuous exercise training (60‐79% of max heart rate), 45-60 min, 3 times/week for 8 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional therapy (antiretroviral therapy and counseling only)
Number of subjects: 30
Study: 23013802

Group type: EXPERIMENTAL
Intervention: Propranolol (1 mg intravenously every 6 hours for 7 days) and Clonidine (0.1 mg per tube every 12 hours for 7 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Propranolol and Clonidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Double placebo
Number of subjects: 0
Study: 20006165

Group type: EXPERIMENTAL
Intervention: Oral propranolol 10 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 18835099

Group type: EXPERIMENTAL
Intervention: Acidic phosphate buffer (pH 5.2) at 40 ml/h
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Acidic phosphate buffer (pH 5.2) at 20 ml/h
Number of subjects: 72

Group type: COMPARATOR
Intervention: Normal phosphate buffer (pH 7.3) at 40 ml/h
Number of subjects: 72

Group type: COMPARATOR
Intervention: Isotonic saline at 40 ml/h
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Acidic phosphate buffer (pH 5.2)
Number of subjects: 72
Study: 16438016

Group type: EXPERIMENTAL
Intervention: Cisatracurium Bolus (0.15 mg/kg) - Group A
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Cisatracurium Infusion (0.18 mg/kg/h) - Group B
Number of subjects: 38
Study: 12885803

Group type: EXPERIMENTAL
Intervention: Rhenium-188 hydroxyethylidenediphosphonate (HEDP) - two injections (group B)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Rhenium-188 hydroxyethylidenediphosphonate (HEDP) - single injection (group A)
Number of subjects: 64
Study: 10475142

Group type: EXPERIMENTAL
Intervention: Oral administration of distigmine (14C-distigmine-bromide)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous administration of 14C-distigmine-bromide
Number of subjects: 0
Study: 9096856

Group type: EXPERIMENTAL
Intervention: Chromium nicotinic acid supplementation (200 micrograms)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 19
Study: 1912107

Group type: EXPERIMENTAL
Intervention: Biperiden 2 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Biperiden 4 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Biperiden 8 mg
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 6356324

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0
Study: 29465346

Group type: EXPERIMENTAL
Intervention: Tocilizumab 4 mg/kg with methotrexate
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Tocilizumab 8 mg/kg with methotrexate
Number of subjects: 299

Group type: EXPERIMENTAL
Intervention: Tocilizumab (both dosages)
Number of subjects: 299
Study: 27344118

Group type: EXPERIMENTAL
Intervention: HHH (chronic cigarette, alcohol, and marijuana use)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DDD (delayed/late‐starting cigarette, alcohol, and marijuana use)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LML (low/no smoking, moderate alcohol use, occasional marijuana use)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HMN (chronic smoking, moderate alcohol use, no marijuana use)
Number of subjects: 0

Group type: COMPARATOR
Intervention: NON (occasional alcohol use only)
Number of subjects: 0
Study: 25826889

Group type: EXPERIMENTAL
Intervention: Modified skull traction surgery (trial group)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Traditional skull traction surgery (control group)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 90
Study: 23248957

Group type: EXPERIMENTAL
Intervention: Concentrated suture fixation method
Number of subjects: 114

Group type: COMPARATOR
Intervention: Packaging group (traditional suture-package fixation method)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Packaging group
Number of subjects: 114
Study: 19800061

Group type: EXPERIMENTAL
Intervention: GnRH antagonist (0.25 mg/d on days 1, 2, and 3 of the menstrual cycle)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control group (no GnRH antagonist supplementation)
Number of subjects: 53
Study: 18341675

Group type: EXPERIMENTAL
Intervention: Phosphodiesterase 4 inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16841667

Group type: EXPERIMENTAL
Intervention: Gegen Qinlian Decoction (GQD) combined with insulin treatment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional group (insulin treatment alone)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: GQD group
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 30
Study: 12646745

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (DFNa)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Betamethasone phosphate (BMS)
Number of subjects: 200
Study: 11813767

Group type: EXPERIMENTAL
Intervention: Intervention to increase mammography compliance
Number of subjects: 817
Study: 9121664

Group type: EXPERIMENTAL
Intervention: 14G intravenous catheter
Number of subjects: 114

Group type: COMPARATOR
Intervention: 16G intravenous catheter
Number of subjects: 114
Study: 7688829

Group type: EXPERIMENTAL
Intervention: Flutamide (375 mg p.o. daily)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Chlormadinone acetate (CMA) (100 mg p.o. daily)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Flutamide
Number of subjects: 54

Group type: COMPARATOR
Intervention: CMA
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Flutamide and CMA
Number of subjects: 54
Study: 2953226

Group type: EXPERIMENTAL
Intervention: Intracoronary nicardipine (0.2 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no nicardipine)
Number of subjects: 12
Study: 31175197

Group type: EXPERIMENTAL
Intervention: Power estimations of non-primary outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systematic use of power estimations
Number of subjects: 0
Study: 30463608

Group type: EXPERIMENTAL
Intervention: Enhanced usual care with financial incentives (up to $550) for participating in the New York Smoker's Quitline, using nicotine replacement therapy, and achieving biochemically confirmed smoking cessation at 2 months and 6 months.
Number of subjects: 182

Group type: COMPARATOR
Intervention: Enhanced usual care without financial incentives (usual smoking cessation care).
Number of subjects: 182
Study: 26306520

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim administration 24 hours after chemotherapy (cohort A)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim administration 72 hours after chemotherapy (cohort B)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Pegfilgrastim administration 96 hours after chemotherapy (cohort C)
Number of subjects: 41
Study: 24865694

Group type: EXPERIMENTAL
Intervention: Low-dose CTPA (80 kVp, 75 ml CM)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Normal-dose CTPA (100 kVp, 100 ml CM)
Number of subjects: 501
Study: 22418088

Group type: EXPERIMENTAL
Intervention: 480 mg choline/d
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 930 mg choline/d
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Higher maternal choline intake
Number of subjects: 47

Group type: COMPARATOR
Intervention: Pregnant women
Number of subjects: 47
Study: 20422401

Group type: EXPERIMENTAL
Intervention: Computer-assisted surgery total knee arthroplasty (CAS-TKA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional total knee arthroplasty (TKA)
Number of subjects: 60
Study: 17910601

Group type: EXPERIMENTAL
Intervention: 2-hour mid-day nap
Number of subjects: 0

Group type: COMPARATOR
Intervention: Melatonin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wakefulness
Number of subjects: 0
Study: 16492649

Group type: EXPERIMENTAL
Intervention: Uncertainty management intervention combining cognitive behavioral strategies and a self-help manual
Number of subjects: 244

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 244
Study: 11950408

Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg preoperatively
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 10559571

Group type: EXPERIMENTAL
Intervention: Tacrine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 7722137

Group type: EXPERIMENTAL
Intervention: Directional atherectomy
Number of subjects: 1012

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 1012
Study: 2039963

Group type: EXPERIMENTAL
Intervention: Telebrix 38 (2% solution in water)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Gastrografin (2% solution in water)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Telebrix 38
Number of subjects: 55

Group type: COMPARATOR
Intervention: Gastrografin
Number of subjects: 55